PipelineReview. Business Intellegence Center

Proteins and Peptides

4 June 2016

Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20

3 June 2016

ADI-PEG 20 plus Gemcitabine and nab-Paclitaxel Shows Robust Anti-tumor Activity in Advanced Pancreatic Cancer

1 June 2016

Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Leber’s Hereditary Optic Neuropathy

28 May 2016

Semaglutide Demonstrated Superior Glycemic Control vs Insulin Glargine U100 in Adults with Type 2 Diabetes

28 May 2016

Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma

27 May 2016

SIPPET, an international randomized study, reports 87% higher incidence of inhibitors with recombinant factor VIII in patients with severe hemophilia A

27 May 2016

U.S. FDA Approves CSL Behring’s AFSTYLA® — The First and Only Recombinant Factor VIII Single Chain Therapy for Hemophilia A

27 May 2016

Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide) for Paediatric Patients with Short Bowel Syndrome

27 May 2016

FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes

25 May 2016

Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230

25 May 2016

Baxalta Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)

25 May 2016

IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee

24 May 2016

Allergan’s BOTOX Vista® (botulinum toxin type A) Receives National Marketing Authorisation in Japan for Treatment of Crow’s Feet Lines in Adult Patients

19 May 2016

Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study

19 May 2016

Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI

16 May 2016

Novo Nordisk files for regulatory approval in the US of long-acting factor IX for the treatment of haemophilia B

14 May 2016

Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B

12 May 2016

European Commission Approves IDELVION® –CSL Behring’s Novel Hemophilia B Treatment with Up to 14-day Dosing Intervals

10 May 2016

Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery

9 May 2016

Avelas Biosciences Announces Positive Interim Phase 1b Results and Advances to Dose Expansion Stage

6 May 2016

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

5 May 2016

Horizon Pharma plc Completes Target Enrollment of 90 Patients for Phase 3 Trial of ACTIMMUNE(R) (interferon gamma-1b) for the Treatment of People With Friedreich’s Ataxia

5 May 2016

Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol® for the Treatment of Moderate to Severe Dry Eye Disease

5 May 2016

Zealand announces top-line results of Helsinn’s Phase IIb trial with elsiglutide for the prevention of chemotherapy-induced diarrhea in colorectal cancer patients

29 April 2016

Allergan Receives CHMP Positive Opinion For ENZEPI® (Pancrelipase) For Patients With Exocrine Pancreatic Insufficiency (EPI)

28 April 2016

European Commission Approves Surgical Patch TachoSil® (human thrombin/human fibrogen) for Use in Neurological Surgery

28 April 2016

Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial

26 April 2016

Alizé Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome

18 April 2016

Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401

18 April 2016

Preclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition in Increasing Clonality of the T Cell Receptor (TCR) Repertoire and T Cell Tumor Infiltration

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

SubscribeNewsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

SubscribeNewsletter new product alert

Featured reports

TSLP Pipeline Review
2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics
RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective
Ustekinumab (Stelara) Biosimilars Pipeline Review
Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists
Ranibizumab (Lucentis) Biosimilars Pipeline Review
Report Package: TCR-Based Antibody and T-Cell Immunotherapy
PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies: a business, pipeline and competitor analysis from an industry perspective
CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review
Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends